Table 3 Clinical characteristics of HBV-infected patients with and without hepatic steatosis after PSM

Age

39.71 ± 9.33

39.79 ± 9.27

0.332

Gender (M/F)

219/35

219/35

/

Height

167.76 ± 6.61

167.62 ± 7.98

0.796

Weight

64.19 ± 9.27

73.01 ± 10.73

< 0.001

BMI

22.79 ± 2.94

25.98 ± 3.56

< 0.001

WBC

5.77 ± 1.60

6.01 ± 1.37

0.066

PLT

183.13 ± 53.90

191.55 ± 52.99

0.068

ALB

44.09 ± 3.45

44.53 ± 3.40

0.093

GLB

28.61 ± 3.89

29.03 ± 4.01

0.212

Tbil

16.10 ± 6.50

16.51 ± 6.31

0.456

ALT

41.76 ± 35.98

52.08 ± 37.54

0.001

AST

33.46 ± 19.05

35.84 ± 17.61

0.132

GGT

31.25 ± 30.39

42.90 ± 36.33

< 0.001

ALP

84.67 ± 21.86

89.56 ± 25.49

0.015

HBV DNA (Log₁₀ IU/mL)

4.22 ± 2.51

4.25 ± 2.51

0.436

HbeAg (+)

88 (34.65%)

88 (34.65%)

/

Anti-viral therapy

16 (6.30%)

16 (6.30%)

/

Hypertension

12 (4.72%)

32 (12.60%)

0.002

T2DM

3 (1.18%)

13 (5.12%)

0.011